NASDAQ:OPGN - OpGen Stock Price, Price Target & More

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen (NASDAQ:OPGN) announced its quarterly earnings results on Thursday, March, 15th. The medical research company reported ($1.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.38) by $0.05. The medical research company earned $0.99 million during the quarter, compared to the consensus estimate of $0.81 million. OpGen had a negative return on equity of 1,719.89% and a negative net margin of 479.38%. View OpGen's Earnings History.

OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for OpGen.

2 analysts have issued 12 month price objectives for OpGen's stock. Their forecasts range from $9.00 to $9.00. On average, they expect OpGen's stock price to reach $9.00 in the next year. View Analyst Ratings for OpGen.

Some companies that are related to OpGen include EnteroMedics (RSLS), Bio-Path (BPTH), Cellectar Biosciences (CLRB), Cesca Therapeutics (KOOL), Prana Biotechnology (PRAN), Cormedix (CRMD), ESSA Pharma (EPIX), Sonoma Pharmaceuticals (SNOA), TrovaGene (TROV), ValiRx (VAL), Fibrocell (FCSC), Cyclacel (CYCC), Cytori Therapeutics (CYTX), Achieve Life Sciences (ACHV), Xenetic Biosciences (XBIO), Ultima (N4P), Biocept (BIOC) and Ritter Pharmaceuticals (RTTR).

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

Media coverage about OPGN stock has been trending positive recently, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OpGen earned a media sentiment score of 0.44 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 45.71 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

OpGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (5.17%) and SABBY MANAGEMENT, LLC (5.17%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $2.05.

OpGen has a market capitalization of $10.84 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]